Overview

Vortioxetine for Posttraumatic Stress Disorder

Status:
Completed
Trial end date:
2020-02-06
Target enrollment:
Participant gender:
Summary
Post-traumatic stress disorder (PTSD) can result from having experienced or witnessed a traumatic event. Patients with PTSD symptoms can sometimes experience symptom relief after treatment with antidepressants; however, few patients experience complete symptom relief. There is a need to develop new treatments for PTSD. This study will evaluate if 12 weeks of using Vortioxetine relieves PTSD symptoms. Vortioxetine has been approved for the treatment of depression; however, Vortioxetine has not been approved by the Food and Drug Administration for the treatment of PTSD.
Phase:
Phase 4
Details
Lead Sponsor:
University of Miami
Collaborators:
Emory University
Takeda
Treatments:
Vortioxetine